LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Aandelen Lijst・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Gesloten

SectorGezondheidszorg

50.55 -2.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

50.43

Max

51.96

Belangrijke statistieken
By Trading Economics
Inkomsten	882M 2.2B
Verkoop	-47M 12B
K/W Sectorgemiddelde	17.397 77.671
EPS	1.46
Dividendrendement	4.76
Winstmarge	17.959
Werknemers	34,100
EBITDA	1.3B 4.6B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+1.28% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	4.76% 2.35%

Marktinformatie
By TradingEconomics
Marktkapitalisatie	16B 105B
Vorige openingsprijs	52.81
Vorige sluitingsprijs	50.55

Nieuwssentiment

By Acuity

25%

75%

63 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

N/A / 50.57 Steun & Weerstand

Bristol-Myers Squibb Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 okt 2025, 11:14 UTC

Winsten

Bristol Myers Squibb 3Q Profit Soars, Raises Revenue Guidance

10 okt 2025, 12:32 UTC

Acquisities, Fusies, Overnames

Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion

31 jul 2025, 11:14 UTC

Winsten

Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q

20 nov 2025, 13:00 UTC

Winsten

This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy. -- Barrons.com

6 nov 2025, 20:02 UTC

Acquisities, Fusies, Overnames

Biotech M&A Deals Are Trickier Than They Look. Watch the Milestone Payments. -- Barrons.com

30 okt 2025, 16:52 UTC

Acquisities, Fusies, Overnames

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera -- WSJ

30 okt 2025, 16:52 UTC

Acquisities, Fusies, Overnames

Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ

30 okt 2025, 11:32 UTC

Winsten

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis, Which Was More Than Offset by Expected Continued Generic Impact Across Remainder of Legacy Portfolio >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: Revised 2025 Adj EPS Guidance Inclusive of 80c Loss Per Shr Net Impact Related to Acquired IPRD Charges and Licensing Income >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 3Q Adjusted Gross Margin 72.9% >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 3Q U.S. Revenue Rose 1% to $8.33B >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb Raises 2025 Rev Guidance to $47.5B-$48B Vs Prior Outlook $46.5B-$47.5B >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: Raised 2025 Rev Guidance Primarily Reflects Continued Strong Performance of Growth Portfolio >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 3Q International Revenue Rose 6% to $3.89B >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: 3Q Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Reblozyl, Camzyos and Breyanzi >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 3Q Legacy Portfolio Rev Fell 12% to $5.37B >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb Adjusts 2025 View To Adj EPS $6.40-Adj EPS $6.60 Vs Prior Outlook $6.35-$6.65 >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 3Q Gross Margin 71.9% >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 3Q Growth Portfolio Revenue Rose 18% to $6.86B >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: Latest 3Q Includes Net Impact of Loss of 20c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 3Q Adj EPS $1.63 >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 3Q Rev $12.22B >BMY

30 okt 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 3Q EPS $1.08 >BMY

10 okt 2025, 16:19 UTC

Acquisities, Fusies, Overnames

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10 okt 2025, 11:02 UTC

Acquisities, Fusies, Overnames

Bristol-Myers Squibb to Pay $1.5B in Cash at Closing to Acquire Orbital >BMY

10 okt 2025, 11:01 UTC

Acquisities, Fusies, Overnames

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics

4 aug 2025, 11:59 UTC

Winsten

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

31 jul 2025, 11:54 UTC

Winsten

Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update

31 jul 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY

Peer Vergelijking

Prijswijziging

Bristol-Myers Squibb Co. Prognose

Koersdoel

By TipRanks

1.28% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 52.33 USD 1.28%

Hoogste 68 USD

Laagste 36 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bristol-Myers Squibb Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

18 ratings

Buy

Hold

Sell

Gebaseerd op 18 analisten die aandelenratings hebben gegeven aan Bristol-Myers Squibb Co. - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

N/A / 50.57Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

63 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.